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Objectives - To identify the most cost effective treatment strategy in patients with early stage (T1and 
T2) cancers of the laryngeal glottis.  
Design - A Markov decision model populated using data from updated systematic reviews and meta 
analyses, with attributable costs from NHS sources. Data on local control and mortality was obtained 
from updates of existing systematic reviews conducted for the NICE guideline on cancer of the upper 
aerodigestive tract. Procedure costs were sourced from NHS reference costs 2013/14 by applying 
tariffs associated with the appropriate health resource group code 
Setting – The UK National Health Service 
Population - Patients with early stage (T1 and T2) cancers of the laryngeal glottis 
Interventions - Transoral laser microsurgery (TLM) and radiation therapy (RT)  
Main outcome measures – Total costs, incremental costs and quality adjusted life years (QALYs) over 
a ten-year time horizon.  
Results - RT as the initial treatment strategy was found to be more expensive (£2,654 vs £623) and 
less effective (QALY reduction of 0.141 and 0.04 in T1a and T1b-T2 laryngeal cancer respectively) than 
TLM. The dominance of TLM for T1a cancers was unchanged in most scenarios modelled in sensitivity 
analysis. For T1b-T2 laryngeal cancers, the result changed in numerous scenarios. In probabilistic 
sensitivity analysis, TLM was found to have a 71% and 58% probability of being cost-effective in T1a 
and T1b-T2 laryngeal cancer, respectively. 
Conclusions - TLM is a cost effective strategy to adopt in the management of T1a laryngeal cancers. 










Early carcinomas of the laryngeal glottis (T1 and T2 tumours) are typically treated with either radical 
radiotherapy (RT) or transoral laser microsurgery (TLM). Although level 1 evidence is lacking, the 
literature is replete with studies that confirm both modalities are equally effective from an oncologic 
perspective1. It is inevitable that the side-effect profile of these treatment modalities will be different 
in the short term, but no studies have categorically revealed differences in functional outcomes using 
existing measures. The data and experience accumulated regarding the treatment of this disease has 
resulted in   most patients with mid-cord lesions being offered TLM; however, when the tumour 
reaches the anterior commissure, surgical resection of this area can have greater effects on the voice, 
and RT may be the preferred option.  
There is little evidence to demonstrate cost-effectiveness of either treatment modality within the UK 
heath care system. The aim of this analysis was to estimate the cost-effectiveness of initial treatments 
for newly diagnosed T1 or T2 carcinoma of the laryngeal glottis in the National Health Service (NHS) 
in the UK. The analysis was conducted as part of the National Institute for Health and Care Excellence 
(NICE) guideline on cancer of the upper aerodigestive tract (NG36)1. 
Methodology 
A de novo economic evaluation was undertaken to assess cost-effectiveness. A Markov decision model 
was developed using Microsoft Excel (figures 1 and 2).  
Patients newly diagnosed with T1-T2 carcinoma of the larynx enter the model and receive primary 
tumour treatment with either RT or TLM. Following treatment with RT, there is a small chance that 
patients may have a non-functioning larynx that necessitates a subsequent total laryngectomy, after 
which the patient will be monitored in a follow-up programme. All other patients treated with either 
TLM or RT will be entered into a follow-up programme. There is then a chance that the patient may 
develop recurrence at which point further treatment with one of multiple treatment options would 
be given. The proportion of patients receiving each of the treatment options was estimated by the 
guideline committee and are discussed in greater detail in a later section of the report. It should be 
noted that the subsequent treatment options are dependent upon preceding treatments (for example 
RT is an option for recurrent tumours in patients initially treated with TLM but not for patients initially 
treated with RT).  
Following treatment of a recurrent tumour, the patient is once again monitored in a follow-up 
schedule where further recurrences may be detected and treated with one of multiple treatment 
options. This pattern continues until the patient undergoes a total laryngectomy at which point 
treatments for localised disease have been exhausted. Patients could die from cancer of the upper 
aerodigestive tract or other cause mortality at any point in the process. 
Recurrence rates for T1a laryngeal cancer patients undergoing RT or TLM were estimated using data 
on progression free survival from the clinical evidence review conducted for the NICE guideline on 
upper aerodigestive tract cancers. A meta-analysis1 of 14 observational studies2-15 in 1855 patients 
with stage T1a disease was the primary source of data. The recurrence rate for patients treated with 
RT was based upon the local control rate of 89.3% observed in patients receiving this treatment. A 
relative risk of 0.99 was then estimated and this used to estimate local control rates in patients treated 
with TLM (88.5%). These values were then converted to annual recurrence rates of 2.05% and 2.21% 
for patients treated with RT and TLM, respectively (assuming a constant rate of recurrence over the 
follow-up period).  
While differences in recurrence rates have been modelled in the base case, it should be noted that 
the slight difference in local control rates was not found to be statistically significant. The uncertainty 
around the difference in local control rates was explored in sensitivity analysis.  
In the absence of high quality comparative evidence for the T1b-T2 laryngeal group, observational 
evidence was used. A systematic review by O’Hara et al16 found that 3-year local control rates were 
lower in patients treated with TLM (76.8%) rather than RT (86.2%). These were converted to annual 
recurrence estimates of 6.56% and 2.99% for the TLM and RT arms respectively (assuming a constant 
rate of recurrence over the time period).  
It was assumed that there were no recurrences after five years of being recurrence free. This is 
intended to reflect clinical practice where recurrences after this time period are very rare.   
Disease-related mortality was captured in the model using data from a meta-analysis1 of 11 
observational studies3-6,8-10,12-15 in patients with stage T1a disease treated with TLM and RT. An odds 
ratio (OR) of 1.55 was reported for disease specific survival, suggesting a slight benefit in patients 
treated with TLM. However, as above, this difference in survival was not found to be statistically 
significant (OR 95% CI 0.75 to 3.20). It was therefore assumed that there was no difference in disease 
specific mortality in the base case analysis.  
A combined mortality rate was estimated using the disease specific survival observed in T1a patients 
treated with RT or TLM in the studies (98.0% over a follow-up period of 5-139 months). This value was 
then converted to an annual mortality rate of 0.4% (assuming a constant rate of mortality over the 
follow-up period). In the base case, these values were also applied to T1b-T2 laryngeal cancer patients. 
However, alternative mortality rates were explored in one-way sensitivity analysis. Death from other 
causes was captured using 2011-2013 life tables for England and Wales from the office of national 
statistics (ONS)17.  
There are numerous treatment options available for patients that experience recurrence. The 
treatment proportions for recurrent patients that were initially T1a and treated with RT were 
estimated from a survey of current UK practice by Paleri et al. 2012 (personal communication). All 
other treatment proportions for recurrent patients were estimated by the guideline committee based 
on their experience in clinical practice. The treatment proportions following recurrence are shown in 
tables 1 and 2 for patients initially treated with RT and TLM, respectively. 
Table 1: Post-recurrence treatment options for patients with T1a and T1b-T2 cancer of the laryngeal 
glottis initially treated with radiotherapy 
Treatment After first recurrence After second recurrence After third recurrence 
T1a laryngeal cancer 
Total laryngectomy 78% 78% 92% 
Partial laryngectomy 7% 7% 8% 
TLM 15% 15% 0% 
Radiotherapy 0% 0% 0% 
T1b-T2 laryngeal cancer 
Total laryngectomy 90% 90% 92% 
Partial laryngectomy 7% 7% 8% 
TLM 3% 3% 0% 
Radiotherapy 0% 0% 0% 
 
Table 2: Post-recurrence treatment options for patients with T1a and T1b-T2 cancer of the laryngeal 
glottis initially treated with TLM 









T1a laryngeal cancer 
Total laryngectomy 20% 27% 85% 75% 
Partial 
laryngectomy 
15% 20% 15% 0% 
TLM 25% 0% 0% 0% 
Radiotherapy 40% 53% 0% 25% 
T1b-T2 laryngeal cancer 
Total laryngectomy 30% 32% 85% 75% 
Partial 
laryngectomy 
15% 16% 15% 0% 
TLM 5% 0% 0% 0% 
Radiotherapy 50% 53% 0% 25% 









T1a laryngeal cancer 
*In patients without previous radiotherapy 
 
The model estimates total costs and total quality adjusted life years (QALYs) for each treatment 
strategy over the modelled time horizon of ten years, with future values discounted at a rate of 3.5% 
per year as recommended by NICE. The total costs include the cost associated with any treatment, 
monitoring or management strategy that patients undergo. QALYs are the measure of effectiveness 
used in the analysis and they were estimated by combining life year estimates with utility values (or 
QoL weights) associated with being in a particular health state. A full list of the cost and QoL inputs 
applied in the model are detailed in Table 3.  
Table 3: Cost and QoL inputs in the model 
Parameter Value Reference 
TLM treatment cost  £2,034.92 [18] 
Radiotherapy cost  £3,429.56 [18] 
Intensity modulated radiotherapy (IMRT) cost £5,410.96 [18] 
IMRT with concomitant radiotherapy cost  £6,069.11 [18] & [20] 
Partial laryngectomy cost £10,578.56 [18] 
Total laryngectomy cost £14,181.18 [18] 
Valve change costs per annum (after laryngectomy) £600.00 Guideline committee estimate 
Systemic chemotherapy cost £3,555.10 [18] & [20] 
Palliative care cost £7,287.00 [21] 
Follow-up costs 
  
Average number of follow-up sessions in year 1 
after TLM 
8.58 Guideline committee estimate 
Average number of follow-up sessions in year 1 
after RT 
7.58 Guideline committee estimate 
Average number of follow-up sessions in year 2 5.85 Guideline committee estimate 
Average number of follow-up sessions in year 3 3.90 Guideline committee estimate 
Average number of follow-up sessions in year 4 2.00 Guideline committee estimate 
Cost per consultation £86.92 [18] 
Nasendoscopy £115.09 [18] 
Speech and language therapy and dietetics costs   
Average number of sessions during and after TLM 5 Guideline committee estimate 
Parameter Value Reference 
Average number of sessions during and after RT 10 Guideline committee estimate 
Average number of sessions during and after 
partial laryngectomy 
16 Guideline committee estimate 
Average number of sessions during and after total 
laryngectomy 
16 Guideline committee estimate 
Cost per speech and language therapy consultation £120.22 [18] 
Cost per dietetics consultation £80.81 [18] 
QoL Values 
  
Alive with voice box entirely intact  0.8718 [22] 
Alive with part of voice box intact 0.7060 [22] 
Alive without voice box 0.8050 [22] 
End of life (metastatic disease) 0.7363 [23] 
 
The costs considered in the model reflect the perspective of the analysis, thus only costs that are 
relevant to the UK NHS and personal social services were included. These costs include drug costs, 
treatment costs and any other resource use that may be required. Where possible, all costs were 
estimated in 2013-14 prices. The majority of costs were sourced from NHS reference costs 2013/1418 
by applying tariffs associated with the appropriate health resource group (HRG) code. Drug costs were 
calculated using dose and regimen information from the British National Formulary (BNF)19 and 
guideline committee with unit costs sourced from the electronic market information tool (eMit)20.  
The total cost of initial RT was estimated to be £3,430, based upon preparation and delivery costs 
from NHS reference costs18 and assuming that 20 fractions of complex conformal radiotherapy would 
be delivered in the outpatient setting. The cost of TLM was estimated to be £2,035, based upon the 
average inpatient cost of an ‘intermediate mouth or throat procedure’18.  
For those patients receiving a TLM or conventional RT as salvage treatment, the same costs estimated 
for initial treatment were applied. However, patients with late stage recurrences (T3 or T4) undergoing 
RT (estimated to be 30% in the base case) were assumed to receive intensity modulated radiotherapy 
(IMRT). The cost of IMRT was estimated to be £5,411, based upon preparation and delivery costs from 
NHS reference costs18, assuming that 30 fractions would be delivered in an outpatient setting. It was 
further assumed that 50% of patients undergoing IMRT would receive concomitant chemotherapy 
with cisplatin given in two doses of 100mg/m2 at an estimated cost of £65820.  
The costs of salvage treatment with a partial laryngectomy (£10,579) or total laryngectomy (£14,181) 
for patients that experience a recurrence were sourced from NHS Reference costs18. It was assumed 
that adjuvant IMRT would be performed for 60% of patients undergoing total laryngectomy if they 
have not previously been irradiated. It was further assumed that 50% of those patients that receive 
IMRT would receive concomitant chemotherapy with two doses of cisplatin.  
The cost per follow-up consultation was estimated to be £86.92 based upon the average cost of an 
ENT and Maxillofacial surgery attendance from NHS reference costs18. It was also assumed that a 
nasendoscopy would be performed at each visit which, based on NHS reference costs, was estimated 
to cost £115.0918. The number of follow-up visits typically required after each treatment was 
estimated by the guideline committee.  
Based on the average cost of attendances from NHS reference costs, a dietetics session and speech 
and language therapy session were estimated to cost £80.81 and £120.22, respectively18. The number 
of sessions required after each treatment modality were estimated by the guideline committee.  
Local audits report that the costs associated with the regular valve changes required in patients after 
a total laryngectomy range from £530-£670 per patient per annum (personal communication with 
guideline committee member). For the purpose of the base case analysis the midpoint of £600 was 
used with variations explored in sensitivity analysis.  
A metastatic cancer state was not explicitly modelled as such. However, it was assumed that patients 
that die from upper aerodigestive tract cancer were likely to have developed metastatic disease. Thus, 
the costs associated with treating metastatic disease as well as the cost of palliative care were applied 
to these patients. It was assumed that 50% of patients would have received systemic chemotherapy 
with a regimen of cisplatin 80mg/m2 (day 1) and fluorouracil 800mg/m2 (day 1, 2, 3 and 4), assumed 
to be given for an average of four cycles. As above, systemic chemotherapy costs were by combining 
drug costs from eMit20 with outpatient administration costs from NHS reference costs18. It was 
estimated that systemic chemotherapy would cost £889 per cycle (£3,555 for 4 cycles). A palliative 
care cost of £7,287 was applied in the model, which was based on a costing report by the Nuffield 
Trust21, which estimated the average resource use of patients with cancer in the last three months of 
life.  
The majority of the QoL values utilised in the analysis were sourced from an existing cost-utility 
analysis by Higgins22. The QoL data were differentiated depending on whether the patient was alive 
with a larynx that was entirely intact, partially intact (i.e. after a partial laryngectomy) or absent (i.e. 
after a total laryngectomy). In addition, a QoL value from the NICE HTA on cetuximab23 was used as 
an estimate for patients in a metastatic disease state. 
Results  
The deterministic base case results of the analysis are presented in Table 4. It can be seen that in both 
T1a and T1b-T2 laryngeal cancer, using RT as the initial treatment strategy was more expensive 
(£2,654 and £623 in T1a and T1b-T2 laryngeal cancer, respectively) and less effective (reduction of 0. 
141 and 0.04 in T1a and T1b-T2 laryngeal cancer, respectively) than transoral laser microsurgery 
(TLM). Therefore, in cost-effectiveness terms, TLM can be considered the dominant strategy i.e. more 
effective and less costly. 
Table 4: Base case cost-effectiveness analysis for early glottis cancer 
Initial treatment  Cost QALYs ICER (cost per 
QALY) Total Incremental Total Incremental 





 6.48  - 
Radiotherapy  £10,857 £2,654 6.34 -0.14 Dominated 








Radiotherapy £11,648 £623 6.23 -0.04 Dominated 
 
A series of deterministic sensitivity analyses were conducted, whereby an input parameter was 
changed, the model re-run and the new cost-effectiveness result recorded. This analysis is a useful 
way of estimating uncertainty and determining the key drivers of the model result. The results of the 
one-way sensitivity analysis are shown in the Table 5. 
Table 5: One-way sensitivity analysis results for T1a and T1b-2 laryngeal cancer 
Change made ICER (cost per QALY gained with RT)  
T1a T1b-T2 
No side effects from RT  RT Dominated RT Dominated 
No difference in local control  RT Dominated RT Dominated 
Upper local control RR = 1.03  RT Dominated - 
Lower local control RR = 0.99  RT Dominated - 
Upper DSS RR = 1.02  RT Dominated RT Dominated 
Lower DSS RR = 0.99  RT Dominated £203,912 
DSS in T1b-T2 laryngeal cancer = 85% - RT Dominated 
DSS in T1b-T2 laryngeal cancer = 75% - RT Dominated 
Upper recurrence and mortality RR  RT Dominated - 
Lower recurrence and mortality RR  RT Dominated - 
No difference in recurrence rates  RT Dominated RT Dominated 
No difference in QoL values  RT Dominated RT Dominated 
Change made ICER (cost per QALY gained with RT)  
T1a T1b-T2 
No discounting  RT Dominated RT Dominated 
Day case costs for TLM  RT Dominated RT Dominated 
TLM cost increased by 50%  RT Dominated £8,995 
TLM cost = radiotherapy cost  RT Dominated £17,492 
Same treatments in TLM and RT after first 
recurrence  
RT Dominated RT Dominant 
Post treatment QoL with RT 0.01 higher than with 
TLM  
RT Dominated £26,232 
Post treatment QoL with RT 0.05 higher than with 
TLM  
£12,134 £2,093 
Recurrence rates maintained over 10 years  RT Dominated RT Dominated 
16 fraction (50 Gy) radiotherapy schedule  RT Dominated RT Dominated 
 
It can be seen that, in the T1a laryngeal cancer group, the conclusion of the analysis is unchanged in 
most modelled scenarios i.e. TLM is found to be the dominant strategy in most analyses. The exception 
to this was when it was assumed that QoL was higher in patients treated with RT. When assuming RT 
was associated with QoL gains of 0.05 it became the most cost-effective strategy with an incremental 
cost-effectiveness ratio (ICER) of £12,280.  
In the T1b-T2 laryngeal cancer group, the analysis was found to be more sensitive with the conclusion 
changing in numerous scenarios. In particular, RT became the most cost-effective intervention when 
TLM costs were increased and in scenarios where a QoL gain was assumed for RT.  
The influence of assuming a QoL benefit for patients treated with RT was further explored in a 
threshold analysis. The analysis showed that, at a threshold of £20,000 per QALY, RT would become 
cost-effective in comparison to TLM when the post treatment QoL with RT was 0.038 and 0.011 higher 
than that with TLM in the T1a and T1b-T2 laryngeal cancer groups, respectively.  
Probabilistic sensitivity analysis (PSA) was conducted to assess the combined parameter uncertainty 
in the model. In this analysis, the mean values that are utilised in the base case are replaced with 
values drawn from distributions around the mean values. The results of 10,000 runs of the PSA are 
shown using ICER scatterplots and a cost-effectiveness acceptability curve (CEAC) in Figures 3, 4, 5 and 
6. The ICER scatter plots show the incremental costs and QALYs associated with each of the 10,000 
runs of the PSA along with the mean result. The CEAC graphs show the probability of each strategy 
being considered cost-effective at the various cost-effectiveness thresholds on the x axis.  
The ICER scatterplot depicted in Figure 3 shows the incremental cost-effectiveness pairs for a 
comparison between RT and TLM in patients with T1a laryngeal cancer. The majority of the results 
reside in the North West showing that RT was found to be more expensive and less effective than 
TLM. In the CEAC presented in figure 4 for the T1a laryngeal cancer group, TLM has a 71% probability 
of being cost-effective at a threshold of £20,000 per QALY. 
The ICER scatterplot depicted in Figure 5 shows the incremental cost-effectiveness pairs for a 
comparison between RT and TLM in patients with T1b-T2 laryngeal cancer. The cost-effectiveness 
pairs are spread across all four quadrants of the plane, suggesting that there is considerable 
uncertainty in this analysis. This is reflected in the CEAC presented in figure 6 for the T1b-T2 laryngeal 
cancer group, in which it can be seen that TLM has a 58% probability of being cost-effective at a 
threshold of £20,000 per QALY. 
Discussion: 
Synopsis of key/new findings  
The results of the base case analysis suggest that using TLM as the initial treatment for early stage 
laryngeal cancer is a cost-effective strategy in T1a and T1b-T2 laryngeal cancer. Indeed, TLM was found 
to be dominant in both analyses. However, the sensitivity analysis showed that there was a difference 
in the level of uncertainty around the results with much more uncertainty around the results in T1b-
T2 laryngeal cancer. Taking into consideration the oncologic and the health economic data, the 2016 
NICE guidelines on upper aerodigestive tract cancer 1 recommends that TLM be offered as first choice 
intervention for patients with T1a glottis cancer.  
Strengths and drawbacks of the study  
This is the first study to have systematically assessed cost-effectiveness of TLM and RT for early glottis 
cancers, applicable to the National Health Service in the UK. As with most economic analyses, this 
analysis is, to some extent, dependent on the clinical data upon which it is based. A systematic review 
was undertaken to ensure that the model inputs reflect the best clinical evidence currently available; 
however, the evidence base was found to have limitations. In both T1a and T1b-T2 laryngeal cancer 
groups, observational studies were used as the main source of clinical data.  
There was also found to be a paucity of quality of life data in this area. The key QoL values applied in 
this model were sourced from Higgins et al. 201122 which was not without limitations. Firstly, since 
the study was Canadian, it may not be directly applicable to the UK context. Secondly, QoL was 
measured using the Health Utilities Index Mark 3 rather than the NICE preferred EQ-5D. Thirdly, the 
small sample size (n=30) limits the certainty that can be placed in the QoL values that were obtained. 
While these limitations may affect the reliability go the QALY results obtained, it should be noted that 
the quantity of QALY benefits was not found to be a crucial determinant of the model result. In both 
scenarios, TLM was found to be dominant (i.e. more effective and cheaper), thus it is the direction of 
the QoL values that is of most importance and these conform to expectations.  
 
Comparisons with other studies 
With the publication of several observational studies and pooled analyses, the medical community is 
in agreement that no evidence exists to show superiority of RT or TLM in local control or overall 
survival. RT may be associated with less measureable perturbation of voice as compared to surgery, 
but no significant differences in patient perception exist24. A recent systematic review of eight 
retrospective cohort studies describing 362 patients with a mean follow up of 47 months concluded 
that no significant difference in post-treatment Voice Handicap Index, a validated outcome measure, 
existed between these two treatments25.  
Recent studies have shown a shift towards TLM as a preferred treatment for T1a glottic cancers26. It 
is unlikely that a randomised controlled study will be performed to generate higher level evidence 
since previous UK-based trials regarding this (EASTER) failed to recruit adequately27. While it is 
primarily the clinical and patient factors that should be taken into consideration to plan the 
appropriate treatment for any given patient, cost effectiveness data can influence the treatment plan 
if equipoise exists.   
To date, no studies have performed a cost effectiveness assessment of TLM versus RT for early glottic 
cancer in the UK setting. A cost-effectiveness analysis considering the Canadian health care system22 
found TLM to dominate RT with higher QALYs and lower costs. A cost analysis study from Canada 
showed that RT was approximately four times more expensive than TLM28. A study of the itemised 
average costs of RT and TLM in the American health care system in 2001 showed RT to be 15.5 times 
costlier29. Using the 5-year survival rate as the “effect” in a cost effectiveness analysis, Diaz-de-Cerio 
et al30 found that TLM offered a saving of €1342.68 per year in the Spanish healthcare setting, 
concluding that TLM was the dominant option for T1 and T2 glottic cancers.  
Conclusion 
The results of the analysis suggest that using transoral laser microsurgery as the initial treatment for 
early stage laryngeal cancer is a cost-effective strategy in T1a and T1b-T2 laryngeal cancer. However, 
in the case of T1b-T2 laryngeal cancer, the result was found to be very sensitive to the changes made 
in deterministic and probabilistic sensitivity analysis. Therefore, the optimal strategy, in cost-
effectiveness terms, remains uncertain in patients with T1b-T2 laryngeal cancer. 
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